Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | BCR | P11274 | 1/20 | 0.39 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | UBE2N | P61088 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | COMT | P21964 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25238794 | 0.90 | CA1 (0.50) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL29605064 | 0.89 | CA1 (0.49) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL26930315 | 0.87 | L3MBTL1 (0.46) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL30674367 | 0.87 | L3MBTL1 (0.46) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL2888387 | 0.84 | L3MBTL1 (0.48) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL23148125 | 0.84 | L3MBTL1 (0.48) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL29813487 | 0.84 | L3MBTL1 (0.48) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL26930421 | 0.83 | L3MBTL1 (0.53) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL30674331 | 0.83 | L3MBTL1 (0.53) | L3MBTL1CA1CA2POLBALDH3A1 | |
| SCHEMBL23147511 | 0.82 | CA1 (0.47) | L3MBTL1CA1CA2POLBALDH3A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147812-B2 | Tyrosine analogues derivatives as Rho-kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-10-19 | — | — | US | disclosed |
| EP-3679039-B1 | TYROSINE ANALOGUES DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-06-16 | — | — | EP | disclosed |
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | CHIESI FARMACEUTICI S.P.A. (IT) | 2021-03-23 | — | — | US | disclosed |
| EP-3573987-B1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARM SPA (IT) | 2021-03-10 | — | — | EP | disclosed |
| US-20210023080-A1 | TYROSINE ANALOGUES DERIVATIVES AS RHO-KINASE INHIBITORS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-01-28 | — | — | US | disclosed |
| WO-2019048479-A1 | TYROSINE ANALOGUES DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2019-03-14 | — | — | WO | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | US | disclosed |
| WO-2018138293-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | CHIESI FARMACEUTICI S.P.A. (IT) | 2018-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210023080-A1 | TYROSINE ANALOGUES DERIVATIVES AS RHO-KINASE INHIBITORS | ROCK1, ROCK2, RHOA | L3MBTL1 4572/4885CA1 4128/4885CA2 850/4885 |
| US-11147812-B2 | Tyrosine analogues derivatives as Rho-kinase inhibitors | ROCK1, ROCK2, RHOA | L3MBTL1 4572/4885CA1 4128/4885CA2 850/4885 |
| US-10954236-B2 | Tyrosine amide derivatives as Rho-Kinase inhibitors | ROCK1, ROCK2, CIT | L3MBTL1 4317/4885CA1 4062/4885CA2 779/4885 |
| US-20180215758-A1 | TYROSINE AMIDE DERIVATIVES AS RHO- KINASE INHIBITORS | ROCK1, ROCK2, CIT | L3MBTL1 4317/4885CA1 4062/4885CA2 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.